FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
about
Melanoma: oncogenic drivers and the immune systemThe vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsIntratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.Hepatic gene transfer as a means of tolerance induction to transgene productsRole played by CD4+FOXP3+ regulatory T Cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteersTumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedMalignant B cells induce the conversion of CD4+CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphomaProfile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancerRoles of the immune system in skin cancer.Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapyAnti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesIsolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal statusExploiting the curative potential of adoptive T-cell therapy for cancer.Skin-resident T cells: the ups and downs of on site immunity.Influence of human immune cells on cancer: studies at the University of Colorado.The suppressive tumor microenvironment: a challenge in cancer immunotherapy.Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Melanoma vaccines: developments over the past 10 years.Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells.Dermal mast cells affect the development of sunlight-induced skin tumours.Immune alterations in malignant melanoma and current immunotherapy concepts.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment.Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.Skin Immunity.Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.
P2860
Q26775598-B95333E4-9EC9-45EB-A951-A054E48B9991Q30423165-04985DCD-6150-407E-8C8C-EDCA7BAAA9CFQ30434822-711B390D-1AAF-4555-BAB3-0DE01B15D783Q33488520-A081519A-CAD9-4FD4-9614-F9F950460CD2Q33737660-D94C786F-43F0-487C-8F26-3BD6DE679D59Q33775537-BF8CC4C1-867B-4304-9334-50F9AEBAF4BCQ33862584-295CF8BC-6920-4655-8FCF-E3C312DD0D7AQ34080914-82FB9762-CE06-4836-AD00-455E4EDF99CFQ34103249-8D685C07-B11D-438C-8264-734D946826C3Q34338725-AC7F1A1F-8836-47EA-A4D1-4750A67FF72FQ34445730-4B8E83CD-7547-4583-8A4D-9AD67D5F03BAQ35077586-DAC9F1D7-D44D-4780-95E7-6AC50BA74E7DQ35232006-693C78B8-6840-4EE1-B297-A7FF06C1A100Q35403714-CAAD0553-96EC-49FE-AE2C-E6F66A32AEB7Q35563824-D0F56961-D0A7-42DB-BE8E-934F0348BC22Q35871756-DDD7B65A-8BC8-466C-B7A2-34731D4EF2AEQ36057563-2BB74E29-4444-483F-A680-838ABD6CA097Q37055402-D77C3960-4D8A-42EE-8B11-B77A0F91D57BQ37107516-0FB01EBC-03A5-41C0-B4B6-A2E7E38A9B3FQ37115223-2FCEACA7-4242-4570-B478-97FC6EEE95F8Q37245083-630676CD-D9A0-4A4F-933F-0047273E5F36Q37274068-3284AC6A-494B-4EF2-BD2D-FC62149126D9Q37444552-1828EC8B-A5DF-4C5F-A74E-3987E5686534Q37576033-9E73AE26-53B3-42C2-8FEB-D21D0EDCCD9BQ37579039-8559B899-99BF-4757-AAA9-691B3305FF12Q37698684-722363A9-385F-4E32-A4A8-F3701B6C1122Q37872288-35743B56-F607-4DD2-BBBA-2937D99A51A1Q37873379-43E1D346-2199-4BB2-BE98-649992D27C0DQ37892595-39E88E3A-BA9A-4DB6-8005-2ADAF295D40AQ37945304-1B380317-E88B-4C39-A1ED-DE9E5B687DB0Q37952804-C584A3CE-3994-4CB4-BCC1-0F3F60B4AC19Q37960189-5D2745ED-F915-4000-9BD6-A55CC5CA153AQ37978661-C8AC87E9-51DC-4F0E-BDD7-EBCB463CBBD5Q38127733-A4E665A2-E10D-4AB8-872F-32A8BE62410DQ38198735-6CD9087F-6057-4EEB-A3AE-E6752F98518FQ38286374-4C5E2EE9-94A8-4EAD-BF21-9234C073194CQ38797446-707AB2E4-433B-4375-BE72-752932CFDB69Q39264898-728AEC14-16BB-441A-A451-E3DF8F7C339EQ39379300-E356C101-FB74-43D0-B80E-82B8891FF28CQ39628656-8DD5EB06-C860-4C94-8774-9505E3FF0B43
P2860
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@ast
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@en
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@nl
type
label
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@ast
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@en
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@nl
prefLabel
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@ast
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@en
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@nl
P2093
P2860
P1433
P1476
FOXP3 expression accurately de ...... in metastatic melanoma lesions
@en
P2093
Aloisio Felipe-Silva
Bianca Heemskerk
Daniel J Powell
John R Wunderlich
Maria J Merino
Mojgan Ahmadzadeh
Steven A Rosenberg
P2860
P304
P356
10.1182/BLOOD-2008-06-163048
P407
P577
2008-09-26T00:00:00Z